ReviewPost ScreenClinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway
Introduction
The unmistakable pungency of capsaicin, a component of chilli peppers, and other natural products that act at the ‘vanilloid receptor’ has led to much basic research into TRPV1 function and an appreciation that this ion channel acts as a key signalling complex in the pain pathway [1]. TRPV1 is primarily found on small diameter primary afferents, particularly unmyelinated C-fibres and thinly myelinated A-δ fibres but is also expressed, albeit at apparently lower levels, in upstream parts of the pain pathway such as the spinal cord and brain 2, 3, 4. Besides being activated by capsaicin (Fig. 1), TRPV1 also responds to a wide range of exogenous and endogenous chemical ligands (e.g. ‘endovanilloids’ such as anandamide) as well as changes in more diverse activators such as protons (acid, pH < 6) and physical stimuli such as heat (>42°C) 5, 6, 7. TRPV1 is also subject to regulation by changes in membrane potential and this intrinsic voltage-dependence is thought to underlie the gating mechanism of this non-selective cation channel [8] which leads to the influx of Na+ and Ca2+ ions into cells. Importantly, TRPV1 activity is also subject to regulation by a host of intracellular signalling cascades that are implicated in the response to algogenic agents, inflammatory mediators and injury (Fig. 2). Overall, this points towards a role of TRPV1 as a key integrator of a diverse array of activators and downstream regulatory pathways that can act in concert to recruit or enhance TRPV1 activity in parts of the peripheral and central nervous system resulting in ongoing or ‘inappropriate’ neuronal activity that may ultimately be perceived as chronic pain.
Characterisation of TRPV1 knockout (KO) mice, which were engineered to lack both copies of the TRPV1 gene, provided pivotal evidence for the key role of TRPV1 in pain. Although phenotypically normal, and virtually inseparable from their littermates in terms of behaviour, these animals show a clear attenuation of the thermal hyperalgesia associated with inflammation 9, 10. These findings provided a strong rationale for the development of selective TRPV1 antagonists as a novel pain therapy with the potential for an improved side effect profile compared to current agents 11, 12. In the period of extensive research that has followed, many novel selective and chemically diverse TRPV1 antagonists have been identified and assessed in preclinical models of pain. For example, BCTC, AMG9810, A425619 and SB-705498 all show good activity in the Freund's complete adjuvant (FCA) model of inflammatory pain 13, 14, 15, 16. Such agents appear to be able to reduce thermal and mechanical hyperalgesia as well as tactile allodynia. Furthermore, TRPV1 antagonists also show efficacy in models of neuropathic pain [15], postoperative pain, cancer pain [17] and the mono-iodoacetate model of osteoarthritis [18]. These data therefore extend the findings of the TRPV1 KO studies and provide a robust pre-clinical rationale for exploring the potential of TRPV1 antagonists for the treatment of a broad range of acute and chronic pain conditions in humans. It is noteworthy that there is also renewed excitement regarding the development of TRPV1 agonist therapies for which recent clinical data have defined the efficacy of injectable and dermal (topical) patch formulations of relatively high concentrations of capsaicin in the treatment of osteoarthritic pain of the knee and in HIV-induced neuropathy. Such approaches capitalise on the desensitising properties of capsaicin but are limited to topical application owing to the issues of systemic side effects associated with capsaicin administration (Table 1). The progress in this field has been reviewed extensively elsewhere [19].
In this article, we will discuss recent progress defining the therapeutic potential of small molecule TRPV1 antagonists as novel analgesic agents and review the current clinical candidates and emerging clinical data for this highly competitive area of drug discovery. The broad therapeutic potential of TRPV1 antagonists for a range of additional indications has been reviewed recently 20, 21, 22 and alternative biological strategies such as the use of antibodies or RNA inhibition to reduce TRPV1 function are also now showing promise (Table 1), but will not be discussed further here.
Section snippets
Mechanistic insight into the contribution of TRPV1 to the pain pathway
Following the identification of several selective TRPV1 antagonists that serve as valuable research tools, a recent work regarding the role of TRPV1 in pain has focused on understanding the site and biological mechanism(s) of action. A recent study by Cui et al., using potent TRPV1 antagonists with either high (A-784168) or low CNS penetration (A-795614) delivered either systemically (orally) or intrathecally or intracerebroventricularly provided evidence for peripheral, spinal and supraspinal
TRPV1 antagonists in development
To date, the available public information suggests that at least seven orally active TRPV1 antagonist molecules have progressed into clinical development (Fig. 3 and Table 2). This may be expected to increase dramatically in the near future on the basis of the progression of compounds from preclinical development (Fig. 4) and early stage research that is underway at several pharmaceutical and biotechnology companies; indeed, the level of R&D investment in TRPV1 antagonists is somewhat
Pharmacological effects of TRPV1 antagonists in humans and their implications
The first data on the effects of TRPV1 antagonists in humans are beginning to appear. Results from a first time into human (FTIH) study with SB-705498 in healthy volunteers demonstrated the effects broadly consistent with its preclinical pharmacology [38]. The compound significantly elevated heat pain thresholds in normal skin compared with placebo, confirming the role of TRPV1 as a heat sensor in humans. Capsaicin-evoked flare, which is known to result from the activation of
Safety profile of TRPV1 antagonists
Even though preclinical safety and toxicology packages have been assimilated for the five compounds that have successfully completed Phase 1 clinical trials (Table 2), relatively little data are yet to be found in the public domain. The obvious success in the progression of multiple chemical entities with potent TRPV1 antagonist activity into preclinical development and into the clinic points towards an overall encouraging profile for this class; however, some new biological findings of note
Perspectives for TRPV1 antagonists as novel therapeutic agents for the treatment of pain
TRPV1 antagonists offer a new mechanism of action for the potential treatment of a wide range of acute and chronic pain disorders. Should the initial promise from preclinical and Phase 1 work discussed above be borne out by emerging data from PoC studies conducted in patients then the TRPV1 antagonist class of compounds may offer one of the first novel mechanistic treatments for pain for many years. In targeting a novel receptor, these agents offer the potential for an improved side effect
Disclosure statement
The authors are employees of GlaxoSmithKline PLC and hold shares in this company.
Acknowledgement
The authors are grateful to Dr David Witty (GlaxoSmithKline) for expert input into the content of Figure 3, Figure 4.
References (70)
Cloning and functional expression of a human orthologue of rat vanilloid receptor-1
Pain
(2000)The diversity in the vanilloid (TRPV) receptor family of ion channels
Trends Pharmacol. Sci.
(2002)Biochemistry and pharmacology of endovanilloids
Pharmacol. Ther.
(2007)- et al.
The TRPV1 receptor and nociception
Semin. Cell Dev. Biol.
(2006) - et al.
The therapeutic potential of TRPV1 (VR1) antagonists: clinical answers await
Drug Discov. Today: Ther. Strat.
(2004) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia
Neuron
(2002)Inflammatory mediators potentiate pain induced by experimental tissue acidosis
Pain
(1996)TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation
Eur. J. Pharmacol.
(2006)Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats
Neuropharmacology
(2005)Role of TRPV1 receptors in descending modulation of pain
Mol. Cell Endocrinol.
(2008)
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans
Pain
Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1
Bioorg. Med. Chem. Lett.
The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans
Pain
Psychophysics, flare, and neurosecretory function in human pain models: capsaicin versus electrically evoked pain
J. Pain
Acute pain mechanisms
Surg. Clin. North Am.
OARSI recommendations for the management of hip and knee osteoarthritis. Part II. OARSI evidence-based, expert consensus guidelines
Osteoarthritis Cartilage
Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study
Pain
Mechanisms of neuropathic pain
Neuron
On the thermoregulatory perils of TRPV1 antagonism
Pain
TRPV1 gene required for thermosensory transduction and anticipatory secretion from vasopressin neurons during hyperthermia
Neuron
Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat
Neuroscience
[3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution
Brain Res.
TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons
Neuron
Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system
J. Biol. Chem.
Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development
Bioorg. Med. Chem. Lett.
The vanilloid receptor: a molecular gateway to the pain pathway
Annu. Rev. Neurosci.
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Nature
Hot receptors in the brain
Mol. Pain
Biochemical pharmacology of the vanilloid receptor TRPV1. An update
Eur. J. Biochem.
The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels
Nature
Impaired nociception and pain sensation in mice lacking the capsaicin receptor
Science
Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia
Nature
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties
J. Pharmacol. Exp. Ther.
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats
J. Pharmacol. Exp. Ther.
Cited by (200)
Lipid raft disruption as an opportunity for peripheral analgesia
2024, Current Opinion in PharmacologyDiscovery of N-(1-(2-hydroxyethyl)quinolin-2-one)-N’-(1-phenyl-1H-pyrazol-5-yl)methyl) urea as Mode-Selective TRPV1 antagonist
2024, Bioorganic and Medicinal Chemistry LettersPotential applications of P2X3 receptor antagonists in the treatment of refractory cough
2023, Respiratory MedicineNeuroprotective effect of transient receptor potential Vanilloid 1 agonist capsaicin in Alzheimer's disease model induced with okadaic acid
2023, International ImmunopharmacologyResearch progress and challenges of TRPV1 channel modulators as a prospective therapy for diabetic neuropathic pain
2023, European Journal of Medicinal ChemistryCitation Excerpt :Notably, the boundary between doses to achieve reversible desensitization and irreversible neurotoxicity remains unclear, and the mechanism of downstream molecular post-calcium influx is unexplained [24]. In various animal models of neuropathic pain, antagonizing or desensitizing TRPV1 channels and downregulating their expression demonstrate analgesic effects [25]. TRPV1 agonists can desensitize the receptor to depict analgesic effects.
Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist
2022, European Journal of Medicinal Chemistry